Moma Therapeutics Inc.

Deals report: Astellas-AviadoBio in CNS gene therapy deal, Merck-Mestag to identify inflammatory targets, Eli Lilly-KeyBioscience tackling obesity

Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,

Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer

Plus: Jones hired as CBO at MOMA, and updates from Metrion, OPPI, 4BIO and Quotient

Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T

Plus: Arrowhead trades up as $450M follow-on extends runway and updates from Remix, CG Oncology, Agios, Boehringer-Ribo, Enyo

Plus: Jeff Albers joins Scorpion as strategic adviser, and updates from Mironid, 1859, mbiomics and Tevogen

Plus: High leaving AskBio, and updates from Verily, PhRMA, MOMA and more 

The firm has backed 11 companies since the start of 2021; none are single-asset plays

Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and more